These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6368615)

  • 1. A regulatory view of the Medicines Act in the United Kingdom.
    Andrews PA; Thompson GM; Ward C
    J Clin Pharmacol; 1984 Jan; 24(1):6-18. PubMed ID: 6368615
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pharmacology in the United Kingdom.
    Smith RN
    Clin Pharmacol Ther; 1974 Sep; 16(3):605-15. PubMed ID: 4412474
    [No Abstract]   [Full Text] [Related]  

  • 3. Licensing and provision of medicines in the United Kingdom. An appraisal.
    Collier J
    Lancet; 1985 Aug; 2(8451):377-81. PubMed ID: 2862524
    [No Abstract]   [Full Text] [Related]  

  • 4. Licensing under the Medicines Act and its effect on pharmacy.
    Fishburn AG
    R Soc Health J; 1974 Dec; 94(6):271-3, 95. PubMed ID: 4460083
    [No Abstract]   [Full Text] [Related]  

  • 5. Legislation covering the licensing of veterinary medicines in the United Kingdom.
    Morgan WJ
    Vet Rec; 1983 Oct; 113(14):310-3. PubMed ID: 6649346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicines, governments and doctors.
    Dunlop D
    Drugs; 1972; 3(5):305-13. PubMed ID: 4652594
    [No Abstract]   [Full Text] [Related]  

  • 7. Overhauling oversight--European drug legislation.
    Tsang L
    Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compensating the drug victim.
    Lancet; 1978 Jul; 2(8079):26. PubMed ID: 78220
    [No Abstract]   [Full Text] [Related]  

  • 9. Crying wolf on drug safety.
    Br Med J (Clin Res Ed); 1982 Jan; 284(6311):219-20. PubMed ID: 6799107
    [No Abstract]   [Full Text] [Related]  

  • 10. Unwanted drug effects: whose responsibility?
    Lancet; 1979 Jul; 2(8132):21. PubMed ID: 87894
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing the safety of medicines.
    Mansel-Jones D
    J R Coll Gen Pract; 1973 Jun; 23 Suppl 2(Suppl 2):67-70. PubMed ID: 4766237
    [No Abstract]   [Full Text] [Related]  

  • 12. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Bull (Edinb); 1981 Nov; 39(6):356-66. PubMed ID: 7035401
    [No Abstract]   [Full Text] [Related]  

  • 13. Law, ethics and morality: the practising veterinary surgeon and the Medicines Act.
    Porter AR
    Vet Rec; 1974 Nov; 95(18):407-11. PubMed ID: 4457095
    [No Abstract]   [Full Text] [Related]  

  • 14. Post-marketing surveillance in the UK (1984).
    Lawson DH
    Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):71S-75S. PubMed ID: 3567035
    [No Abstract]   [Full Text] [Related]  

  • 15. [The safety and registration of pharmaceuticals from the point of view of the medical practitioner].
    Kaiser RH
    Anaesthesist; 2002 Dec; 51(12):1029-37; quiz 1037-8. PubMed ID: 12583351
    [No Abstract]   [Full Text] [Related]  

  • 16. Open letter to UK Prime Minister David Cameron and Health Secretary Andrew Lansley on safety of medicines.
    Archibald K; Coleman R; Foster C
    Lancet; 2011 Jun; 377(9781):1915. PubMed ID: 21641471
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug regulation in the United Kingdom.
    Dollery CT
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 2):689-93. PubMed ID: 1269209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Communicating adverse drug reactions.
    Lancet; 1978 Jan; 1(8056):133. PubMed ID: 87560
    [No Abstract]   [Full Text] [Related]  

  • 19. The medicines act and "me-too" drugs.
    Drug Ther Bull; 1976 Aug; 14(17):65-6. PubMed ID: 964134
    [No Abstract]   [Full Text] [Related]  

  • 20. Are the drug-regulatory agencies paper villains?
    Smith T
    Br Med J; 1980 Nov; 281(6251):1333-5. PubMed ID: 7002251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.